Robert Maslo
Family Medicine · Des Plaines, ILNPI 1972892677
Payments from drug & device makers
Across 163 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$409
- Johnson & Johnson$324
- AstraZeneca$242
- Boehringer Ingelheim$211
- Lilly USA, LLC$188
- Amgen$164
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,68599%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 27 | $409 |
| Johnson & Johnson | 14 | $324 |
| AstraZeneca | 14 | $242 |
| Boehringer Ingelheim | 11 | $211 |
| Lilly USA, LLC | 13 | $188 |
| Amgen(2 entities) | 9 | $164 |
| Amarin Pharma, Inc. | 9 | $146 |
| Currax Pharmaceuticals LLC | 9 | $131 |
| AbbVie(2 entities) | 6 | $123 |
| Supernus Pharmaceuticals, Inc. | 7 | $108 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $103 |
| Pfizer | 5 | $100 |
| Amneal Pharmaceuticals LLC | 5 | $84 |
| Merck | 4 | $61 |
| Shire North American Group Inc | 2 | $47 |
| Astellas Pharma US Inc | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 3 | $39 |
| Sanofi Pasteur Inc. | 2 | $36 |
| GSK | 2 | $31 |
| Novartis | 1 | $24 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Adlon Therapeutics L.p. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| IBSA Pharma Inc. | 1 | $12 |
| Nalpropion Pharmaceuticals LLC | 1 | $12 |
| Abbott | 1 | $12 |
How this compares
$2,699 in reported general payments places this provider in the 85th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 74 | $123,091 |
| MounjaroTirzepatide | 62 | $71,854 |
| EliquisApixaban | 48 | $56,834 |
| JardianceEmpagliflozin | 33 | $54,001 |
| JanuviaSitagliptin Phosphate | 26 | $37,634 |
| RybelsusSemaglutide | 22 | $34,046 |
| WegovySemaglutide | 19 | $24,916 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $12,118 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $6,703 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $3,817 |
| Atorvastatin Calcium | 388 | $3,742 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $3,184 |
| Arnuity ElliptaFluticasone Furoate | 15 | $3,125 |
| Metoprolol Succinate | 103 | $2,304 |
| Levothyroxine Sodium | 171 | $2,137 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $409 | $182,054115 claims |
| Lilly USA, LLCMounjaro | $188 | $71,85462 claims |
| PfizerEliquis | $100 | $56,83448 claims |
| Boehringer IngelheimJardiance | $211 | $54,00133 claims |
| MerckJanuvia | $61 | $37,63426 claims |
| GSKBreo Ellipta, Arnuity Ellipta | $31 | $9,82829 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $84 | $2,137171 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Des Plaines
- Luis Gonzalez OrozcoDes Plaines$892K
- Nigam PatelDes Plaines$34K
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.